# Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ARQT
## Company Profile
- Ticker: ARQT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 26.23 USD
- Market cap: 2600483345.46 USD
- Last updated: 2026-08-11
## Business Overview
### Medical Dermatology
Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology.
### ZORYVE Franchise
ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic dermatitis and seborrheic dermatitis.
### Pediatric Expansion
Arcutis is seeking to extend ZORYVE cream to infants with atopic dermatitis and ZORYVE foam to younger children with scalp and body plaque psoriasis.
### New ZORYVE Indications
Phase 2 proof-of-concept studies are evaluating ZORYVE foam in vitiligo and hidradenitis suppurativa.
### ARQ-234
ARQ-234 is a biologic candidate in initial clinical development for moderate-to-severe atopic dermatitis, expanding Arcutis beyond topical PDE4 inhibition.
## Why The Stock Is Moving

As of Aug 11, 2026, ARQT closed up 1.20% at $26.23. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA review milestones for the ZORYVE cream infant-atopic-dermatitis sNDA.
- Phase 2 vitiligo results and an advancement decision in the fourth quarter of 2026.
- Phase 2 hidradenitis-suppurativa results and an advancement decision in the first quarter of 2027.

## Recent News
- 2026-08-07 20:00 EST — [Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-662493df) — Source: Arcutis Biotherapeutics
- 2026-08-05 20:00 EST — [Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ARQT/arcutis-announces-second-quarter-2026-financial-results-and-provides-business-up-b7ecdf90) — Source: Arcutis Biotherapeutics
- 2026-07-16 13:00 EST — [Arcutis Expands Board of Directors with Appointment of Chris Peetz](https://biopharmsignal.com/news/ARQT/arcutis-expands-board-of-directors-with-appointment-of-chris-peetz-301b4fb5) — Source: Arcutis Biotherapeutics
- 2026-07-15 20:00 EST — [Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026](https://biopharmsignal.com/news/ARQT/arcutis-to-report-second-quarter-2026-financial-results-and-host-conference-call-00bbf84b) — Source: Arcutis Biotherapeutics
- 2026-07-08 12:00 EST — [FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months](https://biopharmsignal.com/news/ARQT/fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-roflumilast-cre-09abb4cc) — Source: Arcutis Biotherapeutics